Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Wong ND, Fan W, Philip S, et al. REDUCE-IT eligibility and preventable cardiovascular events in the US population (from the National Health and Nutrition Examination Survey [NHANES]). Am J Cardiol. 2020; epub ahead of print.

https://www.ajconline.org/article/S0002-9149(20)30861-4/fulltext
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).

Nelson AJ, Navar A, Mulder H, Wojdyla D, Philip S, Granowitz C, Peterson ED, Pagidipati NJ. Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial). Am J Cardiol. 2020; epub ahead of print.

Toth P, Granowitz C, Hull M, Philip S. Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis. J Manag Care Spec Pharm. 2018;24(4 suppl a):S70-S71.

https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.4-a.s1

Leatherman S, Ferguson RE, Hau C, Granowitz C, Harrington K, Philip S, Toth P, Bhatt D, Boden WE.Residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides across the cardiovascular risk spectrum [abstract]. J Am Coll Cardiol 2020;75(11 suppl 1):1980.

http://www.onlinejacc.org/content/75/11_Supplement_1/1980

Lakshmanan S, Shekar C, Dahal S, Onuegbu A, Kinninger A, Cai A, Birudaraju D, Cherukuri L, Golub I, Rezvanizadeh V, Dailing C, Flores F, Hamal S, Roy SK, Nelson J, Budoff MJ. Association of HDL subclasses with baseline coronary plaque burden by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract]. J Am Coll Cardiol 2020;75(11 suppl 1):1624

http://www.onlinejacc.org/content/75/11_Supplement_1/1624

Lakshmanan S, Shekar C, Dahal S, Onuegbu A, Kinninger A, Cai A, Rezvanizadeh V, Golub I, Birudaraju D, Cherukuri L, Hamal S, Dailing C, Flores F, Roy SK, Nelson J, Budoff MJ. Association of inflammatory markers with baseline coronary plaque volumes by coronary computed tomography angiography (CCTA) from EVAPORATE (effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy) trial [abstract]. J Am Coll Cardiol 2020;75(11 suppl 10:1720. 

http://www.onlinejacc.org/content/75/11_Supplement_1/1720

Toth P, Granowitz C, Hull M, Philip S. Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database [abstract]. J Am Coll Cardiol. 2019;73:1744.

http://www.onlinejacc.org/content/73/9_Supplement_1/1744
Leatherman S, Ferguson R, Weir I, et al. Increased residual cardiovascular risk in US veterans and moderately-elevated baseline triglycerides and well-controlled LCL-C levels on statins [abstract]. J Am Coll Cardiol. 2019;73:1719. http://www.onlinejacc.org/content/73/9_Supplement_1/1719

Toth P, Granowitz C, Hull M, Liassou D, Anderson A, Philip S. Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis [abstract]. J Am Coll Cardiol. 2018;71(11 suppl):A1445.

http://www.onlinejacc.org/content/71/11_Supplement/A1445
Bays HE, Philip S, Chowdhury S, Doyle R, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester) in statin-treated patients with elevated cardiovascular risk and very high triglyceride levels: results from the MARINE study [abstract]. J Am Coll Cardiol. 2016;67(suppl):1950. http://www.onlinejacc.org/content/67/13_Supplement/1950

Pagidipati N, Navar A, Mulder H, Wojdyla DM, Philip S, Granowitz CB. Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trialDiabetes. 2019;68(suppl 1):1472P.

http://diabetes.diabetesjournals.org/content/68/Supplement_1/1472-P

Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S, Granowitz C, Navar AM. The Association between Triglycerides and Incident Cardiovascular Disease: What Is “Optimal”? Journal of Clinical Lipidology 2020;14:438-447.

https://www.lipidjournal.com/article/S1933-2874(20)30079-9/fulltext?dgcid=raven_jbs_etoc_email

Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020;41(24):2304–2312.

https://doi.org/10.1093/eurheartj/ehz778

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients. Vasc Health Risk Manag. 2019;15:533-538.

https://www.ncbi.nlm.nih.gov/pubmed/31824165
copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation